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ABSTRACT 
Introduction 
Ku 70/80, a regulator of the Non-Homologous End Joining (NHEJ) has been shown to have 
clinicopathological and prognostic significance in breast cancer (BC) from Caucasian 
populations. However, its significance in the Nigerian BC population, which is characterized by 
a higher rate of triple-negativity, and basal phenotype with high p53 mutation rate and BRCA1 
deficiency, is yet to be investigated.  We hypothesized that Ku70/80 expression would show 
adverse clinicopathological and survival characteristics in Nigerian and also, likely to have 
therapeutic implication on Black BC management.  
Aim 
To investigate the biological, clinicopathological and prognostic significance of Ku 70/80 
expression in a BC cohort from the Nigerian population 
Materials & Methods  
189 well-characterised BC cases were included in the study. Ku 70/80 expression was sought in 
formalin-fixed, paraffin-embedded (FFPE) BC samples from these patients using Tissue 
Microarray and Immunohistochemistry. Ku 70/80 expression was correlated with the 
clinicopathological, molecular and prognostic characteristics of patients. 
Results 
Ku 70/80 was expressed in 113 (60.1%) of tumours and positively associated with metastatic 
disease, triple-negativity, basal phenotype, BRCA1 down regulators (MTA-1 and ID4) p-
cadherin, PI3KCA, p53 expression and inversely correlated with BRCA1, BRCA2, BARD1 and 
p27. Ku 70/80 was predictive of breast cancer-specific survival (BCSS) survival in multivariate 
analysis, but not of disease-free interval (DFI). 
Conclusion 
Ku 70/80 expression is associated with metastatic disease, down-regulation of the Homologous 
Recombination pathway of DNA repair, loss of the G1-S phase checkpoint, high EMT potential 
and poor prognosis. 
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INTRODUCTION  
The Non-Homologous End Joining (NHEJ) is an important cellular DNA double-stranded break 
(DSB) repair mechanism which is undertaken by a complex of proteins including the Ku 
heterodimer, Ku 70/80 [1-4].  The specific functions of the Ku heterodimer include recognition 
of and binding to the DSBs, recruitment of DNA protein kinase c (DNA-PKc) to the ends of the 
DSB. Once bound to the DSB ends the DNA-PKcs undergoes auto-phosphorylation, disengages 
from the damaged ends and allows downstream repair factors, such as Artemis, polynucleotide 
kinase 3’-phosphatase (PNKP), DNA polymerases, the MRN complex, XLF and XRCC4/DNA 
Ligase IV, to access the damaged site [1-4]. Ku 70/80 therefore acts as a regulator of the NHEJ, 
and its expression can be used as a marker for the NHEJ [4]. 
The NHEJ is involved in the repair of DSBs induced by radiation and some chemotherapeutic 
agents such as cyclophosphamide and topoisomerase poisons [1, 5]. In addition, the NHEJ 
process itself is error-prone and therefore induces additional mutations and genomic instability in 
tumour cells [6-11].  Recent studies show that Ku 70/80 is over expressed in tumour more than in 
normal cells [6, 10]. Furthermore, Ku 70/80 protects cancer cells from apoptosis [11]. Ku 70/80 
can therefore be regarded as an oncogene in cancer cells as it promotes tumour progression.  
The prognostic significance of Ku 70/80 expression in relation to clinical, pathological and 
survival indices are organ-specific. In advanced head and neck carcinoma, patients whose 
tumours had higher Ku 70/80 expression show better response to chemotherapy with 5-
fluorouracil and cisplatin [12]. In gastrointestinal malignancies, high Ku 70/80 expression is 
associated with higher gastric cancer clinical stage; with depth of invasion, pathological stage, 
histopathological grade and prognosis in advance colorectal carcinoma. Furthermore, in rectal 
carcinoma its relationship with pathological stage, histopathological grade, radio-sensitivity and 
disease-free interval has been reported [6, 13, 14]. Conversely, in endometrial carcinoma, 
disease-free interval is longer in patients whose tumour show low expression of Ku 70/80. 
However, there was no association between clinicopathological features and other survival 
characteristics [15]. 
A study of a Caucasian BC cohort showed that nuclear expression of Ku 70/80 is associated with 
higher histological grade, lympho-vascular invasion, negative estrogen receptor (ER) expression, 
basal-like phenotype, p53 and checkpoint kinase1 (CHK1) positivity. Ku 70/80 expression also 
showed an association with disease-free interval in univariate but not in multivariate analysis 
[16]. 
In this study we sought to determine the expression of Ku 70/80 in a well-characterised Nigerian 
BC cohort using Tissue Microarray and immunohistochemistry; and compared its expression 
with the clinicopathological and survival characteristics of the patients.  
MATERIALS AND METHODS 
Patients’ characteristics 
The patients included a cohort of Nigerian BC women with adequate data on clinicopathological 
features and survival characteristics, as used in previous studies [17]. Briefly, 189 of formalin-
fixed paraffin embedded (FFPE) breast cases from women presenting at the Olabisi Onabanjo 
University Teaching Hospital, Sagamu, and Histopathology Specialist laboratory, Idi-Araba 
Lagos, Nigeria from January 2002 to December 2008 were included. Clinical history and tumour 
characteristics including age, menopausal status, tumour type, histological grade, tumour size, 
lymph node status and vascular invasion were assessed in a standardised manner for all the 
patients.  
Patient outcome and treatment data were retrieved from the patient’s records. All patients were 
treated with combination of classical chemotherapy cyclophosphamide, methotrexate and 5FU 
and hormonal therapy (tamoxifen). Eighty five out of the patients (about 45%) received 
radiotherapy.  Patients were followed up for at least 60 months (260 weeks). During this follow-
up period; 83 patients (43.9%) died, while 106 patients either remained alive (n= 13, 6.9%) or 
were lost to follow-up (n=93, 49.2%). Forty (40) patients (21.2%) had recurrence within the 
maximum disease-free interval of 15 months (60weeks).   
  
The Reporting Recommendations for Tumour Marker Prognostic Studies (REMARK) criteria, 
recommended by McShane et al [18] were followed. This study was approved by the Medical 
Advisory Committee, Olabisi Onabanjo University Teaching Hospital. 
Western blotting 
The KU 70/80 antibody was first validated using Western blotting as described in [16]. Briefly, 
protein extraction was accomplished using RIPA buffer containing protease and phosphatase 
inhibitors. About 50µg of protein was used to perform a protein gel electrophoresis. The resolved 
proteins were blotted onto a nitrocellulose membrane. Membrane blocking was accomplished 
with a solution of 5% non-fat dried milk in PBS-Tween-20. Primary incubation was performed in 
1:1000 dilution of KU 70/80 mouse monoclonal antibody for 1hour at room temperature. Beta-
actin was used as control. Detection of proteins was performed by chemiluminescence.   
Immunohistochemistry (IHC) staining  
TMAs were constructed as previously described [17]. The expression of markers was determined 
using IHC in 4um TMA sections. The standard strept Avidin–Biotin complex method as 
described in Agboola et al was used for the detection of tissue markers [17]. In each IHC staining 
both positive and negative controls were included. The negative controls were performed by 
omitting the primary antibodies. The sources of primary antibodies, antibodies, positive controls, 
and dilution methods used in this study are shown in Table 1. 
Immunohistochemistry scoring 
The scoring of immunoreacitivty for Ku 70/80 was performed by determining the percentage of 
invasive malignant cells within showing positive staining. All samples were scored by one 
observer (JA) and a further observer (T-AF) countered scored a proportion. The cases were 
scored without knowledge of the patient outcome. The whole tissue mounts and TMA samples 
were scored twice. The mean of the scores were calculated to reach a final score. The median 
score of 74% was used to dichotomise immunoreactivity into high/low groups for subsequent 
analysis. All the other markers used in this study were scored as shown in Table 1   
Statistical Analyses 
Statistical analysis was performed using SPSS 16.0 statistical software. Chi-squared analyses 
were used for inter-relationships between the Ku 70/80 expression, clinicopathological 
parameters and other biomarkers. The Kaplan–Meier survival method and the log-rank test were 
used for survival curves. Multivariate analyses using Cox proportional hazard regression models 
were performed and from the model both the risk factor and 95% confidence intervals were 
generated. A two-sided p-value of <0.05 was considered significant. 
RESULTS 
Western blot confirmed the specificity of Ku 70/80 antibody (Ab3108 Abcam) used in this study.  
The nuclear Ku 70/80 biomarker expression was dichotomised according to the frequency 
histogram distributions using the median of the percentage of the nuclear staining. Zero to 
seventy-four percent (0-73%) staining was considered negative/low expression while 74% and 
above was regarded as positive/ high expression. A total of 113 (60.1%) cases were considered 
positive and 76 (39.9%) were negative/low for Ku 70/80. 
Clinicopathological features of Ku 70/80 expression in Nigerian breast cancer 
Table 2 shows the relationship between the clinicopathological parameters and Ku 70/80 protein 
expression, where the majority of the tumours that expressed Ku 70/80 showed positive vascular 
invasion (p=0.009). There were no other significant associations between Ku 70/80 and other 
clinicopathological characteristics. 
Ku 70/80 expression shows associations with hormone receptors, molecular subtypes, cell 
cycle and DNA repair markers 
The relationship between the Ku 70/80 and other biomarkers expression (Table 3) revealed an 
inverse correlation between oestrogen receptor (ER) and progesterone reactor (PgR), BRCA1-
associated RING domain-1(BARD1), p27 (all p<0.001), HER-2 (p=0.01), Breast cancer 
associated genes 1 (BRCA-1, p=0.004) and (BRCA-2,  p=0.006), Conversely, there was a 
positive correlation of Ku 70/80 expression with cytokeratins: CK5/6  and CK14, BRCA1 down-
regulators (metastasis antigen 1 (MTA1) and Helix-loop –helix protein of differentiation 4 (ID4)) 
protein inhibitor of activated start protein gamma (PIASɣ), Ubiquitin conjugating enzyme 9 
(UBC9), Phosphoinositide 3-kinases (PI3KCA), p53, Epithelia growth factor receptor 1 (EGFR), 
Triple-negative tumour and Basal-like phenotype ( all p<0.001)., cyclin B (p=0.006) and 
Placental (P)-cadherin (p=0.04), There was no significant association between Ku 70/80 with 
ataxia telangiectasia and Rad 3 related (ATR), Epithelia (E)-cadherin or protein inhibitor of 
activated start protein 1 (PIAS1).    
Prognostic significance of Ku 70/80 expression in the Nigerian breast cancer cases 
Multivariate analysis shows that tumours which were positive for Ku70/80 protein expression 
had a significantly poorer BCSS compared to tumours with negative/low Ku70/80 protein 
expression, independent of tumour grade, tumour size and lymph node involvement (Table 4). 
There was no significant association with disease-free interval, DFI.   
DISCUSSION 
Ku 70/80 is one of the key determinants in the DNA damage response [1-4]. The roles of this 
biomarker in relation to clinicopathological parameters, biological behaviour and patients’ 
outcome in BC, particularly in women from an indigenous Black African population, had 
hitherto not been studied. In line with its role in tumour progression, this study found a high 
expression of the NHEJ marker, Ku 70/80, in more than 60% of BC from a Nigerian population 
[6-9, 12-16]. This finding agrees with the rate of expression of Ku 70/80 in clinical cancers 
generally [10, 13, 14, 19].  
In concurrence with previous studies, the expression of Ku 70/80 was associated with adverse 
clinicopathological and survival characteristics: vascular invasion, triple-negative and basal-like 
subtypes of BC, as well as the molecular markers of poor prognosis [12-15]. In particular, these 
findings are similar to the results that were obtained from a UK study [16]. 
 
Ku 70/80 expression was a predictor of poor clinical outcome in Nigerian BC patients, 
independent of tumour grade, size and lymph node involvement. This is the first study to report 
Ku 70/80 association with survival in Nigerian BC. 
The expression patterns of BRCA1, BRCA2, BARD1, p53, MTA, ID4 and Ku 70/80 in this and 
our previous studies imply a down-regulation of the Homologous Recombination pathway (HR) 
in the majority of Nigerian BC patients and the tumours may be depending on the NHEJ 
pathway, a pathway which is adept at repairing cyclophosphamide- and radiotherapy-induced 
DSBs [1, 5, 20, 21].While BRCA1, BRCA2 and BARD1 function in the HR pathway, MTA and 
ID4 are known down-regulators of BRCA1. UBC9 and PIASɣ stabilize Ku 70 to enable the 
DNA repair by NHEJ mechanisms [1, 5, 22-25].  
In this study, Ku 70/80 expression is associated with the epithelial-mesenchymal transition 
(EMT) markers; p-cadherin and PIK3CA [26, 27]. The EMT enables tumour cells to undergo 
invasion and metastasis [26, 27]. This is in line with our finding that Ku 70/80-positive tumours 
had high vascular invasive activities. Loss of p53 function is associated with uninhibited cell 
cycle G1 to S phase transition regulated by the cyclin-cyclin-dependent kinase complexes [28]. 
Therefore, the high expression of cyclin B found in this study may be in keeping with the loss of 
p53 function, i.e. p53 overexpression, seen in Ku 70/80-positive tumours. Furthermore, the p27 
loss, which denotes, in conjunction with p53 loss of function, the absence of the G1 to S phase 
checkpoint, in these Ku 70/80 tumours may be due to increased activity of the PIK3CA pathway 
in our study, since the PIK3CA pathway has been shown to down-regulate p27 [29], this might 
probably induced aneuploidy cells capable of enhancing tumours metastasis. 
With respect to the therapeutic significance of Ku 70/80 expression in our BC cohort, it is 
noteworthy that cyclophosphamide-based chemotherapy, hormonal therapy and radiotherapy 
were offered to many patients in the Nigerian series, and yet the majority of them died within 5 
years of diagnosis [30]. It is plausible to assume that the poor prognosis observed in our BC 
cohort is partly due to the adeptness of tumour cells at repairing therapy-induced DSBs using 
NHEJ pathway, and also, probably subjected them to high resistant rate to chemotherapy and 
radiotherapy [1, 5]. Going further, it might be arguable that there is probably a need to change 
from the current “one-size-fits-all” approach to therapy, where all patients are treated with 
cyclophosphamide-based chemotherapy, to a biomarker-assisted selection of patients for 
chemotherapy and radiotherapy. For example, a study has shown that patients whose tumours 
with higher expression levels of Ku 70/80 respond better to cisplatin and 5-fluorouracil [12] 
Also, low expression of Ku 70/80 was shown to predict good response to radiotherapy in early 
BC [31]. More recently, patients with deficient BRCA1 expression have been shown to respond 
better to cisplatin than patients with proficient BRCA1 expression [32, 33]. Biomarker-assisted 
chemo- and radiotherapy may therefore be a superior strategy for clinical cancer therapy than the 
current approach. A further potential therapeutic implication of the findings in this study is that 
the Ku 70/80 expression pattern in our cohort opens up a possibility of targeting the NHEJ 
pathway in black BC This is particularly important in the triple-negative BC subtype which 
currently has paucity of targeted therapy and commonly occurred among the black women. For 
example, inhibition of the NHEJ pathway such as with DNA-PK inhibitor, Nu7026 was reported 
to sensitize cells to topoisomerase II poisons [34]. Considering that most tumours which show 
high expression of Ku 70/80 in our study are also deficient in BRCA 1 and BRCA 2 (i.e. the HR 
pathway), it becomes even more attractive to target the NHEJ pathway in Nigerian BC cases. In 
many preclinical studies, inhibition of both the HR and NHEJ pathways has been demonstrated 
to enhance therapeutic sensitivity to radiotherapy and chemotherapy [35-38].  
In conclusion, this study has for the first time shown that Ku 70/80 protein expression is high in 
Nigerian BC cases, has adverse clinicopathological significance, defective HR pathway of DNA 
repair, loss of G1-S checkpoint, high EMT potential and also confers poor prognosis. In addition, 
it has revealed a possibility for targeting the DNA repair pathways to improve patients’ outcome 
among the Black BC. 
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Table 1: Sources, dilution, distribution, cut-offs point and pre-treatment used for 
revalidation 
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cells
≥0(positive)  Antigen 
retrieval 
Microwave
Normal breast 
acini
Omitting 
the 
antibody
ID4 Ab773
45
Abcam 1:100 Nuclear % of 
positive 
cells
≥50% 
(positive)
Antigen 
retrieval 
Microwave
Human colon 
cancer
Omitting 
the 
antibody
KU70/
80 Ab310
8
Abcam
1:250
0
Nuclear % of 
positive 
cells
>74% 
(positive)
Antigen 
retrieval 
microwave
Tonsil tissue Omitting 
the 
antibody
MTA 1 Ab841
36
Abcam
1:100 Nuclear
% of 
positive 
cells
≥1% 
(positive)
Antigen 
retrieval 
microwave
Human 
gastric 
adenocarcino
ma
Omitting 
the 
antibody
Table 2: Relationship between KU70/80 expression and clinicopathological parameters in Nigerian 
breast cancer 
P -
cadheri
n
NCL- 
P-cad
Novocast
ra
1:200 Cytoplas
m
% of 
positive 
cells
≥5% 
(positive)
Antigen 
retrieval 
Microwave
Known case 
of P-cadherin 
strong BC  
expression
Omitting 
the 
antibody
PgR PgR Dako-
Cytomati
on
1:150 Nuclear % of 
positive 
cells
≥0 
(positive)
 Antigen 
retrieval 
Microwave
Normal breast 
acini
Omitting 
the 
antibody
PIASγ NBP1-
31215
Novus 
Biologica
ls
1:100 Nuclear % of 
positive 
cells
≥65% 
(positive
 Antigen 
retrieval 
Microwave
Human breast 
carcinoma
Omitting 
the 
antibody
P13KC
A
HPA00
09985
Sigma 1:50 Nuclear % of 
positive 
cells
>60% 
(positive)
Antigen 
retrieval 
microwave
Human breast 
carcinoma
Omitting 
the 
antibody
p27 SX53
G8
Dako-
Cytomati
on
1:10 Nuclear % of 
positive 
cells
≥10% 
(positive)
 Antigen 
retrieval 
Microwave
Normal breast 
acini
Omitting 
the 
antibody
p53 DO7 Novocast
ra
1:50 Nuclear % of 
positive 
cells
>10% 
(negative)
Antigen 
retrieval 
Microwave
Normal breast 
acini
Omitting 
the 
antibody
UBC9 Ep293
8Y
Novus 
Biologica
ls
1:100 Nuclear % of 
positive 
cells
>70% 
(positive)
Antigen 
retrieval 
microwave
Human brain 
tissue
Omitting 
the 
antibody
Variables
                                     KU70/80
Negative/low 
 (%)
Positive  
(%)
χ2 value p-value
Age (years) 
≤ 50 
> 50
48 (64.0) 
27 (36.0)
73 (64.6) 
40 (35.4)
0.007 0.93
Lymphnode involvement 
Negative 
Positive 5 (6.7) 
70 (93.3)
10 (8.8) 
103 (91.2)
0.29 0.58
Menopausal 
Pre  
Post
47 (62.7) 
28 (37.3)
80 (70.8) 
33 (29.2)
1.35 0.24
Mitotic  figure 
Low  
Medium  
High 
48 (64) 
17 (22.7) 
10 (13.3)
64 (56.6) 
27 (23.9) 
22 (19.5)
1.43 0.49
Nuclear pleomorphism 
Small uniform cells 
Moderate increase in size 
Marked variation
   0 (0.0) 
29 (38.7) 
46 (61.3)
  0(0.0) 
29 (25.7) 
84 (74.3)
3.57 0.06
Size (cm) 
≤2.0 
>2.0
  4 (5.3) 
71 (94.7)
  12 (10.6) 
101 (89.4)
1.61 0.20
Tubule formation 
> 75 % 
10 -75 % 
< 10 %
  2 (2.7) 
  1 (1.3) 
72 (96.0)
    1 (0.9) 
    7 (6.2) 
105 (92.9)
3.45 0.17
Tumour grade 
1 
2 
3
  3 (4.0) 
45 (60.0) 
27 (36.0)
  1 (0.9) 
64 (56.6) 
48 (42.5)
2.61
0.27
Tumour type 
Typical medullary 
Atypical medullary 
Tubular 
Lobular  
Ductal NST 
Mucinous  
Tubulolobular 
Lobular mixed 
Tubular mixed 
Mixed NST 
Others
  1 (1.3) 
  1 (1.3) 
  0 (0.0) 
  0 (0.0) 
67 (89.3) 
  1 (1.3) 
  0 (0.0) 
  2 (2.7) 
  3 (4.0) 
  0 (0.0) 
  0 (0.0)
    0 (0.0) 
    0 (0.0) 
    1 (0.9) 
    2 (1.8) 
105 (92.9) 
     1 (0.9) 
     0 (0.0) 
     1 (0.9) 
     3 (2.7) 
     0 (0.0) 
     0 (0.0)
6.30 0.50
Vascular invasion 
Negative 
Positive
11 (14.7) 
64 (85.3)
32 (28.3) 
81 (71.7)
4.76 0.009
Table 3: Relationship between KU70/80 expression and other biomarkers in Nigeria BC women 
Variables                                      KU 70/80
Negative/low (%) Positive (%) χ2 value p-value
Basal cytokeratin
Ck5/6 
Negative 
Positve
56 (88.9) 
  7 (11.1)
23 (22.5) 
79 (77.5)
68.68 <0.001
CK14 
Negative 
Positive
39 (76.5) 
12 (23.5)
35 (39.8) 
53 (60.2)
17.46 <0.001
BRCA1 down regulators
MTA1 
Negative 
Positive
53 (75.7) 
17 (24.3)
27 (24.5) 
83 (75.5)
45.36 <0.001
ID4 
Negative 
Positive
39 (63.9) 
22 (36.1)
     6 (5.5) 
104 (94.5)
69.20 <0.001
E-cadherin 
Negative  
Positive 
35 (64.8) 
19 (35.2)
56 (65.9) 
29 (34.1)
0.01 0.897
P_cadherin 
Negative 
Positive
27 (50.9) 
26 (49.1)
29 (33.3) 
58 (66.7)
4.25 0.04
CYCLINB1 
Negative 
Positive
39 (65.0) 
21 (35.0)
42 (42.4) 
57 (57.6)
7.61 0.006
P27 
Negative 
Positive
58 (84.1) 
11 (15.9)
60 (60.0) 
40 (40.0)
11.21 <0.001
P53 
Negative 
Positive
27 (61.4) 
17 (38.6)
13 (12.7) 
89 (87.3)
36.52 <0.001
ATM 
Negative 
Positive
70 (93.3) 
5 (6.7)
100 (88.5) 
13 (11.5)
1.21 0.27
BARD1 
Negative 
Positive
68 (97.1) 
2 (2.9)
84 (77.1) 
25 (22.9)
13.41 <0.001
BRCA1 
Negative 
Positive
43 (75.4) 
14 (24.6)
85 (92.4) 
7 (7.6)
8.35 0.004
Table 4: Cox Regression Analysis 
BRCA2 
Negative 
Positive
40 (67.8) 
19 (32.2)
78 (86.7) 
12 (13.3)
7.70 0.006
EGFR 
Negative 
Positive
45 (83.3) 
9 (16.7)
49 (49.5) 
50 (50.5)
16.88 <0.001
HER_2 
Negative 
Positive
45 (72.6) 
17 (27.4)
90 (87.4) 
13 (12.6)
5.69 0.01
P13KCA 
Negative 
Positive
38 (54.3) 
32 (45.7)
28 (25.2) 
83 (74.8)
15.64 <0.001
Steroid hormone receptors
ER  
Negative 
Positive
41(59.4) 
28 (40.6)
96 (87.3) 
14 (12.7)
18.31 <0.001
PgR 
Negative  
Positive
29 (56.9) 
22 (43.1)
90 (90.9) 
  9 (9.1)
23.79 < 0.001
PIAS1 
Negative  
Positive 
27 (54.0) 
23 (46.0)
49 (62.8) 
29 (37.2)
0.98 0.32
PIASγ 
Negative  
Positive 
40 (69.0) 
18 (31.0)
12 (11.7) 
91 (88.3)
55.74 <0.001
UBC9 
Negative  
Positive 
42 (79.2) 
11 (20.8)
  8 (7.8) 
95 (92.2)
82.09 <0.001
Triple negative  
Negative  
Positive 
39 (78.0) 
11 (22.0)
27 (27.0) 
73 (73.0)
35.18 < 0.001
Nielsen classification  
Basal  
HER-2 
Luminal A 
Luminal B
0 (0.0) 
9 (12.0) 
18 (24.0) 
7 (9.3)
67 (59.3) 
9 (8.0) 
10 (8.8) 
1 (0.9)
73.64 < 0.001
FIGURES 
 
Figure 1: Ku 70/80 immunoreactivity positivity (A) and negativity (B) in Nigerian breast 
cancer. Mag x20 
Variables
p-value
Hazard 
ratio
95.0% CI 
Lower Upper
KU70_80 0.004 0.503 0.316 0.800
grade <0.001 2.534 1.618 3.969
size 0.694 1.200 0.483 2.984
lymph_node 0.633 1.239 0.515 2.979
Figure 2 (A) and (B) show Ku 70/80 tumours probability of survival (A) and recurrence (B) 
A B
Negative (n=28)
Positive (n=55)
χ
2
 8.62, p=0.003
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χ2=0.42, p = 0.51
